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~~~-~~~ cathepin D processed htuxan big endcrthelinl_s into ~~d~th~~~~-~k~ fragments bat did not appear to generate e~~~~~~~~~ under 
the conditions empioyed. By contrast, human catbepsin E specifica& cleaved human big endotbelin into endothehn,st and the C-terminal fragment 
under identical conditions but did not degrade ither product farther. 
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1. INTRODUCTION 
Human endothelin (ET) is a 21-residue polypeptide 
produced by endothelial cells. In addition to displaying 
a vasoconstrictor activity more powerful than that of 
angiotensin II [ 13, the peptide produces a number of 
other pharmacologic~ actions [2]. Endothelin is believ- 
ed to be generated by a single proteolytic cleavage of the 
bond linking residues Trp-21-Val-22 (Fig. 1) in its im- 
mediate biosynthetic precursor, big ET, by a hitherto 
unidentified endopeptidase termed endothelin- 
converting enzyme. Since the vasoconstrictor activity of 
big ET is much less potent than that of ET [3,4], inhibi- 
tion of this converting enzyme activity might have con- 
siderably therapeutic value for the treatment of 
hypertension, 
The conversion of big ET to ET is inhibited by 
pepstatin, suggesting the pa~ic~pation of a cellular 
aspartic proteinase [5,6]. Pepsin, if added in high 
enough quantities, will convert big ET in vitro, 
specifically into ET plus CT at pH 2.3 [7] but, 
physiologically, pepsin is unlikely to be the enzyme 
responsible for the processing. The only known aspartic 
proteinases produced in human tissues (apart from the 
gastrointestinal and reproductive tracts) are renin, 
cathepsin D and cathepsin E [8]. It has been reported 
very recently [l&l I] that a cathepsin R-like activity is 
capable of converting big ET into a form that is im- 
munoreactive with antibodies which recognise ET. 
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Under the conditions employed in the present report, 
we demonstrate that purified human or rat caphepsin 
E, but not cathepsin D, converts big ET specifically into 
ET and CT and might thus be considered as a likely can- 
didate for the endothelin-conveying enzyme activity. 
2. MATERIALS AND METHODS 
Synthetic human big ET, ET and CT were obtained from the Pep- 
tide Institute Inc. (Qsaka, Japan). Big ET and CT radio-iodinated 
specifically at Tyr-31 (Fig. 1) were kindly prepared (by Phil Robinson 
in &he Amersham Development Group) using a modification of the 
lactoperoxidase method [X2]. ET and big ET labelled with “‘1 on 
Tyr-13 were from Amersham plc (Bucks, UK). Two radioim- 
munoassays (termed X and Y for convenience of understanding) were 
configured. The X assay was the endothelinl - II specific ‘251-assay 
system (&nersham RPA 555) which has the following cross- 
reactivities: ET 100%; human big ET 0.4%; pig big ET 0.26%; 
human CT <0,003%, The assay has an ED= of - 3 fmoiitube and 
permits the specific detection of ET. The Y assay was the rather less 
specific endotheiin-l,2 (high sensitivity) ‘%assay system (Amersham 
RPA 545) which has the following cross-reactivities: ET lOO%; 
human big ET 189%; pig big ET 63%; human CT ~0.003%. The 
assay has an EDso of - 4.5 fmol/tube, 
Human cathepsin D was prepared from spleen as described 
previously [13] and rat cathepsin D was a kind gift from Dr G. 
Bone&, University of Turin, Italy. Cathepsin E of human/rat origin 
[i4] was generousIy provided by Drs LM. Samloff (V.A. Medical 
Centre, Sepulveda, CA, USA) and Dr K. Yamamoto (Kyushu Univer- 
sity, Japan). Big ET (4 gg; I nmol), ET or CT were incubated 
(separately) for 1,2 or 6 h at 37°C with individual purified proteinases 
(up to 0.1 a; 0.0025 nmol) in SO $ of 0.1 M sodium acetate or citrate 
buffers at the indicated pH values. Reactions were stopped by the ad- 
dition of 200 ~1 of 5% (w/v) TFA prior to loading ahquots (ZOO & on- 
to a Crs Vydac reverse phase HPLC column (Hichrom Ltd., Reading, 
UK). A gradient from 0 to 6OBio acetonitrile containing 0.1% TFA was 
used over 20 min for elution at a flow rate of 2 ml/min. Peak ratcn- 
tion times were identified by chromatography of authentic standards 
of big ET, CT and endothehn. Fractions (0.8 ml) were collected and 
analysed in the X and Y RIAs. When radioiodinated peptides were 
employed, identical assays were performed but with the inclusion of 
0.1 pCi of the appropriate labelled tracer and the use of an HPLC gra- 
dient of 0% to 40% acetonitrile plus 0.1% TFA, followed by isocratic 
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Fig. 1. Structure of human big endothelin. The site required to be 
cleaved to generate ndothelin and release the C-terminal fragment is 
indicated by an arrow. 
elution at 40% acetonitrile and 1 ml/min. Radioactive peaks were 
monitored by means of an in-line loop held within a Roberts tube con- 
nected to a ratemeter (ES1 Nuclear, Ruislip, UK) and receptor. 
Sequencing was performed by automated Edman degradation with 
an Applied Biosystems Model 473 sequencer. 
3. RESULTS AND DISCUSSION 
Initial experiments were carried out by incubating the 
precursor, big ET (4 pg), for I,2 and 6 h at pH 4.7 with 
homogeneous human cathepsin D (0.1 pg). The reaction 
products were analysed by HPLC (Fig. 2a) and RIA 
(Fig. 2b) but only the 6 h data are illustrated since the 
other time points of analysis showed similar patterns of 
digestion. None of the, products observed on reverse 
phase HPLC corresponded to authentic synthetic stan- 
dard ET. Furthermore, no immunoreactivity was 
observed in any of the newly-generated peaks using the 
X RIA which is highly specific for ET (Fig. 2b). By con- 
trast, the much less discriminatory Y RIA indicated ET- 
like immunoreactivity in the fractions eluting between 
the positions of CT and big ET. The peak that eluted 
first on the gradient (Fig. 2a) was not precisely identical 
with the elution position of authentic CT. Its area was 
estimated to be less than 20% of the expected peak size 
if complete conversion to CT itself had occurred. Ex- 
periments performed with [iz51]big ET labelled at posi- 
tion 133 (Fig. 1) confirmed the production of one major 
and one minor labelled ET-like fragment by human 
cathepsin D but no peak of radioactivity corresponding 
to ET was detected in the elution profile (data not 
shown). 
When highly-purified cathepsin D (0.1 pg) from rat 
was incubated for 2 h with big ET (4 pg), multiple 
degradation products were produced (Fig. 2c) but, once 
again, no formation of ET was observed. Thus, it 
would appear that big ET is digested by cathepsin D in 
a more complex manner than the specific generation of 
ET. However, the possibility remained that the conver- 
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Fig. 2. Effect on human big ET of human (a) and rat (c) cathepsin D 
at pH 4.7 and 37°C. Fractions collected from the reverse phase HPLC 
column in (a) were analysed (b) by the X (closed bars) and Y (open 
bars) radioimmunoassays. The positions of elution of authentic CT, 
big ET and ET applied to the HPLC column as markers were as in- 
dicated. 
sion of big ET to ET + CT was slow by comparison 
with the subsequent further degradation of ET/CT. 
This was investigated by incubation of synthetic ET and 
CT, each at 2 pg (separately), for 2 h with human 
cathepsin D (0.1 pg). Fig. 3a shows that ET is indeed 
degraded readily by human cathepsin D whereas CT 
was not affected (Fig. 3b). It is noteworthy that residual 
big ET was still present even after 6 h incubation with 
cathepsin D (Fig. 2a) whereas all of the ET added in- 
itially was destroyed in less than 2 h (Fig. 3a) after addi- 
tion to cathepsin D. Thus, if cathepsin D were to be in- 
volved in the conversion of big ET to ET in vivo, this 
reaction would not appear to be of particular benefit 
biosynthetically, since the destruction of the newly- 
formed ET would be faster than its generation. 
Attention was therefore focussed on the other known 
intracellular aspartic proteinase, cathepsin E. Samples 
of big ET (4 pg) were incubated for 1 and 6 h with the 
homogeneous human enzyme (0.1 pg; a molar ratio of 
4OO:l). The reaction resulted in the generation of two 
peaks (Fig. 4a), the elution positions of which coincided 
exactly with those of CT and ET. Close to complete 
conversion was observed within 2 h. Diminution of the 
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Fig. 3. Effect of human cathepsin D on human ET (a) and CT (b) at 
pH 4.7 and 37°C. 
amount of cathepsin E included in the incubation mix- 
ture to 0.05 or 0.01 pg (i.e. molar ratios of big 
ET/cathepsin E of 800: 1 or 4000: 1) resulted in the con- 
version of approx. 80% and 15%, respectively, of big 
ET in 2 h incubation at 37‘C. In order to confirm the 
identity of the product corresponding in elution posi- 
tion to the authentic C-terminal standard (Fig. 4a), the 
peak was collected and subjected to sequence analysis. 
The complete sequence of this product was: 
V~-Asn-Thr-Pro-Glu-His-Val-V~-Pro-Tyr-Gly-Leu- 
Gly-Ser-Pro-Arg-Ser (repetitive yield = 87.3~0) 
thus indicating specific cleavage by human cathepsin E 
at the site in human big ET (Fig. 1) proposed for the 
endothelin-converting enzyme [ 11. 
The peaks from the HPLC elution were also analysed 
using both RIA methods employing the ET-specific X 
and the less-specific Y RIAs (Fig. 4b). The latter 
recognised both the residual big ET (second peak} and 
the newly-generated third peak (ET) whereas the ET- 
specific X RIA reacted only with the third peak, thus 
identifying it as ET. The availability of the ET specific 
X antibody permits such an unequivocal identification 
of ET consisting of residues 1-21. Such a well- 
characterised specific and sensitive assay was not 
employed for precise immunological identification of 
reaction products in previous reports (e.g. [lo]). Addi- 
tional experiments were also carried out in 0.1 M 
sodium citrate buffers at pH 5.5 and 6.2. (in the 
presence of 6 mM ATP to stabilise the activity of 
cathepsin E [15]). Identical elution patterns were 
observed to that depicted for pH 4.7 in Fig. 4a with con- 
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Fig. 4. Effect of human cathepsin E on human big ET (a) and ET (c) 
at pH 4.7 and 37OC. Fractions (0.8 ml) collected from the reverse 
phase HPLC column in (a) were analyzed (b) by both the X (closed 
bars) and Y (open bars) radioimmunoassays. 
version of approx. 50% and IS%, respectively, of the 
precursor in 2 h by 0.1 cg of cathepsin E. 
Incubation of aliquots of synthetic ET (Fig. 4c) or CT 
(not shown) with human cathepsin E resulted in no pro- 
teolysis of either peptide. It would thus appear that 
human cathepsin E does specifically convert big ET into 
ET plus CT (Fig. 1) with no further degradation 
thereafter. Identical results were also obtained with 
cathepsin E of rat origin (data not shown). When big 
ET radioiodinated at position 13 (Fig. 1) was incubated 
with human cathepsin E, the label was detected on 
radio-HPLC only in the elution position corresponding 
to that of ET. Similarly, when the enzymic digestion 
was performed with the precursor radiolabelled at posi- 
tion 31 (Fig. l), the conversion by human cathepsin E 
paralleled that observed with the non-labelled substrate 
and the isotype was detected by radio-HPLC this time 
in an identical elution position to that of authentic 
]i2’I]CT. 
Finally, overnight incubation at 37’C of human big 
ET (4 kg) with human renin (up to 1 pg) resulted in no 
conversion of the precursor whatsoever. Renin is believ- 
ed to function as an extracellular aspartic proteinase 
whereas cathepsin E and cathepsin D (with the excep- 
tion of transformed cells [16]) are not secretory en- 
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zymes but are both located, albeit in different compart- 
ments, within cells (I.M. Samloff, personal com- 
munication). Thus, it would appear that if a (known) 
aspartic proteinase is to be responsible for the specific 
conversion of big ET to ET as has been suggested 
[IO,1 11, then the reaction ought to take place in- 
tracellularly. The work described herein has focussed 
primarily on human (and to a lesser extent, rat) enzymes 
and it should be emphasised that earlier reports with ex- 
tracts of cells/tissues have been performed with 
material of bovine or porcine origin (e.g. [5,6,10,1 I]). 
It is not clear at present whether the same enzyme is 
responsible for endothelin conversion in all species but 
since blood pressure regulation in man is of con- 
siderable pharmaceutical interest, our ongoing studies 
are directed towards identification of the proteinase in 
endothelial and other [g] cells that catalyses this impor- 
tant reaction. 
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